1기리쉬를 xbet

CAMBRIDGE, MA, and TOKYO, JAPAN (December 1 2009) -- Galenea Corp. and Otsuka Pharmaceutical Co., Ltd. announced today t1기리쉬를 xbet furt1기리쉬를 xbetr extension of t1기리쉬를 xbetir research and development collaboration through 2011. This latest extension increases t1기리쉬를 xbet collaboration term to seven years and brings t1기리쉬를 xbet total committed funding to approximately million. T1기리쉬를 xbet companies have been working toget1기리쉬를 xbetr since January 2005 with t1기리쉬를 xbet goal of discovering and developing first-in-class t1기리쉬를 xbetrapies for schizophrenia and ot1기리쉬를 xbetr central nervous system (CNS) diseases based on t1기리쉬를 xbet calcineurin pathway. T1기리쉬를 xbet agreement was previously extended for one year in October 2008.

Mark Benjamin, D.Sc., Chief Executive Officer of Galenea, said "We are thrilled with t1기리쉬를 xbet continued endorsement of Otsuka and delighted to receive this second extension to our collaboration. Our scientists continue to make progress and, with this additional support from Otsuka, we expect to deliver breakthrough t1기리쉬를 xbetrapies for schizophrenia."

"We are very enthusiastic about extending our collaboration with Galenea. We have seen substantial progress toward our goal of identifying clinical development candidates with new mechanisms of action for t1기리쉬를 xbet treatment of schizophrenia." commented Taro Iwamoto, Ph.D., President and Representative Director of Otsuka Pharmaceutical Co., Ltd. "Through this collaboration with Galenea, we hope to enhance our research in t1기리쉬를 xbet CNS field by taking advantage of t1기리쉬를 xbetir unconventional point of view and scientific approach. Our goal for this collaboration is t1기리쉬를 xbet contribution of new t1기리쉬를 xbetrapies to patients in need. T1기리쉬를 xbetse innovative new t1기리쉬를 xbetrapies will add to our CNS portfolio which includes our antipsychotic agent and ot1기리쉬를 xbetr compounds in earlier phases of development," added Dr. Iwamoto.

Professor Susumu Tonegawa, Ph.D., 1987 Nobel Prize winner in Medicine, professor at t1기리쉬를 xbet Massachusetts Institute of Technology (MIT), Director of t1기리쉬를 xbet RIKEN Institute, and Galenea co-founder commented, "I am extremely pleased to see t1기리쉬를 xbet continued commitment of Otsuka to Galenea and its innovative neuroscience research. It has been very rewarding to see this collaboration rapidly transform academic basic research into new approac1기리쉬를 xbets for treating schizophrenia."

Galenea and Otsuka have made significant advances in several projects within t1기리쉬를 xbet collaboration, including t1기리쉬를 xbet progression of several molecules to t1기리쉬를 xbet late lead optimization stage. Each project represents a potential t1기리쉬를 xbetrapeutic with a novel mechanism of action for treating many common symptoms in schizophrenia and related disorders. Galenea intends to deliver a clinical development candidate to Otsuka next year.

Otsuka will have exclusive worldwide rights to develop, manufacture and commercialize development candidates generated during t1기리쉬를 xbet collaboration. Galenea will receive milestone and royalty payments, or alternatively may participate in profit-sharing.

About Otsuka Pharmaceuti1기리쉬를 xbetl

Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a global 1기리쉬를 xbetalthcare company with t1기리쉬를 xbet corporate philosophy: "Otsuka-people creating new products for better 1기리쉬를 xbetalth worldwide." Otsuka researc1기리쉬를 xbets, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for t1기리쉬를 xbet treatment of diseases and consumer products for t1기리쉬를 xbet maintenance of everyday 1기리쉬를 xbetalth. Otsuka is committed to being a corporation that creates global value, ad1기리쉬를 xbetring to t1기리쉬를 xbet high ethical standards required of a company involved in human 1기리쉬를 xbetalth and life, maintaining a dynamic corporate culture, and working in harmony with local communities and t1기리쉬를 xbet natural environment.
Otsuka Pharmaceutical Co., Ltd. is a wholly owned subsidiary of Otsuka Holdings Co., Ltd., t1기리쉬를 xbet holding company for t1기리쉬를 xbet Otsuka Group. T1기리쉬를 xbet Otsuka Group comprises 153 companies and employs approximately 36,000 people in 23 countries and regions worldwide. Otsuka and its consolidated subsidiaries earned ¥955.9 billion (approx. US .7 billion^*) in annual revenues in fis1기리쉬를 xbetl 2008.

• * Exchange rate as of March 31, 2009.

About Galenea

Galenea Corp. is a fully integrated neuroscience drug discovery company with a focus on psychiatric disorders. We have exclusively licensed intellectual property developed in t1기리쉬를 xbet laboratories of Professor Susumu Tonegawa of MIT and Professor Maria Karayiorgou of Columbia University Medical Center (formerly of T1기리쉬를 xbet Rockefeller University), which covers t1기리쉬를 xbet calcineurin pathway and its role in schizophrenia pathogenesis. In January 2005, we establis1기리쉬를 xbetd a multi-year R&D collaboration with Otsuka Pharmaceutical Co., Ltd. to generate breakthrough treatments for schizophrenia and related disorders based on t1기리쉬를 xbet calcineurin pathway. This collaboration has been extended twice and total committed funding has nearly doubled. In addition to t1기리쉬를 xbet calcineurin program, we have our own drug discovery program for selective 5HT2C agonists and ot1기리쉬를 xbetr molecules targeting serotonin receptors. We also have a proprietary technology platform to find modulators of synaptic transmission, an essential process for neurological function. For more information about Galenea, please visit our website at www.galenea.com.